The researcher: Anuradha Kumar, a postdoctoral researcher working in a team led by Dr. David Sherman, Seattle Biomedical Research Institute, was responsible for conducting this research at the Open Lab.
The sponsor: Seattle BioMed is the largest independent, non-profit organisation in the US focused solely on infectious disease research. Our research is the foundation for new drugs, vaccines and diagnostics that benefit those who need our help most: the 14 million who will otherwise die each year from infectious diseases, including malaria, HIV/AIDS and tuberculosis. Founded in 1976, Seattle BioMed has nearly 350 staff members. By partnering with key collaborators around the globe, we strive to make discoveries that will save lives sooner.
Foundation funding: The Foundation provided £32,137 in support of this research.
GlaxoSmithKline’scontribution: GSK provided in-kind contributions (including facilities, chemical library and expertise from supporting scientists in the TB and Pharmacology units).
Project Description: The emergence of multi drug resistant Mycobacterium tuberculosis (Mtb) strains has highlighted the need for new medicines to treat TB. During her time at the Open Lab, Anuradha Kumar explored how new drugs can be discovered by taking advantage of previously validated drug targets that have not been the focus of current TB treatments.
With access to the large chemical library and the help of medicinal chemists, Anuradha was able to identify novel compounds that make good in-vivo candidates. In addition, these compounds will be optimised in collaboration with pharmacologists experienced with pre-clinical drug development to produce a new antitubercular lead compound with the most potential for success.
“The work at the Open Lab in Tres Cantos is highly collaborative - as well as working with highly skilled teams and the open access to different resources, scientists are able to move the project to experts who meet the specific needs as the research progresses.” (Anuradha Kumar, Open Lab scientist)